Search results
After FDA setback, psychedelic drugmakers distance themselves from a pioneer
Washington Post via Yahoo News· 3 hours agoCORRECTION: A previous version of this article misstated the position of Rick Doblin, founder of the...
Geron wins long-sought drug approval; Califf talks China, GLP-1s at BIO
BioPharma Dive via Yahoo Finance· 3 days agoAfter 34 years, Geron finally has an approved medicine in Rytelo. Elsewhere, Shionogi disclosed...
Africa’s Biggest Drugmaker Sees Move to Vaccine Autonomy
Bloomberg· 6 days agoAfrica’s plans to increase vaccine autonomy are gaining traction as the continent seeks to reduce...
2 High-Yield Dividend Stocks to Buy Right Now | The Motley Fool
The Motley Fool· 4 days agoDividend stocks are sensitive to interest rates. When rates fall, studies show that money managers...
Watch Out Wegovy: Here Comes Another Promising Anti-Obesity Candidate
Motley Fool via Yahoo Finance· 6 days agoSecond, though mazdutide beat dulaglutide in helping patients lose weight in this trial, the latter...
A big problem for psychedelic medicine
Politico· 4 days agoTech Sprint.” Experts from academia, think tanks and a national laboratory rhapsodized to Congress’ Joint Economic Committee on Tuesday about the ways AI...
EDITORIAL: Colorado’s mushroom ‘therapy’ unmasked
Colorado Springs Gazette· 3 days agoFood and Drug Administration decided in a 9-2 vote that pharmaceutical Lykos Therapeutics...MDMA, is not an effective PTSD treatment. It found that the tests the ...
Alphabet names Lilly executive Anat Ashkenazi as CFO By Reuters
Investing.com· 5 days agoAshkenazi's departure from Lilly was announced earlier in the day. At Alphabet (NASDAQ:GOOGL), she...
Top Analyst Reports for Novo Nordisk, TotalEnergies & U.S. Bancorp
Zacks via Yahoo Finance· 2 days agoToday's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks via Yahoo Finance· 2 days agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective...